Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

An Open, Multi-Centre Trial Evaluating Acceptance of the New Liquid Growth Hormone Formulation - Norditropin Simplexx™ in Children With GH Deficiency

This trial is conducted in Asia. The aim of this trial is to evaluate the new liquid somatropin formulation in children with growth hormone deficiency.

Inclusion Criteria:

• Written Informed Consent by patient and/or guardian/parents
• Patients with one of the following diagnosis: Growth failure due to growth hormone deficiency (GHD), Turner syndrome, or growth retardation in children with chronic renal disorders
• Patients who are willing to inject themselves and answer questionnaires or young patients whose parents/guardian are willing to inject their child and answer questionnaires
• Patients on growth hormone therapy for at least 6 weeks before entering the trial

Exclusion Criteria:

• Pregnancy or breast feeding women
• Suspected or known allergy to trial product
• Other daily injection therapy (non-growth hormone, e.g insulin-therapy)
• Participating in any other trial involving other investigational products within the last 3 months